Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MBX Biosciences, Inc. Common Stock (MBX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: MBX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $
1 Year Target Price $
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.39% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 676.25M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 4.81 - 27.50 | Updated Date 06/28/2025 |
52 Weeks Range 4.81 - 27.50 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.48 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 613914658 | Price to Sales(TTM) - |
Enterprise Value 613914658 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 31853700 | Shares Floating 14361705 |
Shares Outstanding 31853700 | Shares Floating 14361705 | ||
Percent Insiders 3.08 | Percent Institutions 54.94 |
Analyst Ratings
Rating 4.6 | Target Price - | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
MBX Biosciences, Inc. Common Stock
Company Overview
History and Background
MBX Biosciences is a biopharmaceutical company pioneering peptide therapeutics to treat endocrine disorders. Founded to address unmet needs in rare endocrine diseases, MBX focuses on developing differentiated peptide-based therapies that precisely target the underlying causes of disease.
Core Business Areas
- Peptide Therapeutics Development: MBX Biosciences specializes in the discovery and development of peptide therapeutics for endocrine disorders.
- Precision Endocrine Targeting (PET) Platform: They utilize their proprietary Precision Endocrine Targeting (PET) platform to create peptide therapeutics with enhanced efficacy and safety profiles.
- Clinical Development: MBX advances its pipeline of peptide therapeutics through preclinical and clinical studies.
Leadership and Structure
MBX Biosciences is led by a management team with expertise in endocrinology, drug development, and business. The company structure supports research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- MBX-2146: MBX-2146 is a clinical-stage peptide therapeutic in development for hypoparathyroidism. There is no available data on market share or revenue for MBX-2146 as it is in clinical development. Competitors in this space include Ascendis Pharma (ASND) and Amolyt Pharma.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the segment focused on endocrine disorders, is characterized by significant unmet medical needs and growing demand for targeted therapies.
Positioning
MBX Biosciences is positioned as an innovator in peptide therapeutics for endocrine disorders, leveraging its PET platform to develop differentiated therapies with the potential for improved outcomes.
Total Addressable Market (TAM)
The total addressable market for endocrine disorder treatments is substantial, estimated to be in the billions of dollars. MBX Biosciences is focused on capturing a share of this market by developing therapies for specific rare endocrine conditions.
Upturn SWOT Analysis
Strengths
- Proprietary PET platform
- Focus on rare endocrine disorders
- Experienced management team
- Strong intellectual property position
Weaknesses
- Early-stage clinical development
- Reliance on funding for research and development
- Limited product portfolio
- High attrition rates typical for biotech companies
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into other endocrine disorders
- Potential for orphan drug designation and market exclusivity
- Advancements in peptide drug delivery technologies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- Ascendis Pharma (ASND)
- Amolyt Pharma
Competitive Landscape
MBX Biosciences competes with established pharmaceutical companies and other biotech companies developing therapies for endocrine disorders. Its competitive advantage lies in its proprietary PET platform and focus on rare endocrine conditions. However, no market share is currently available as it is pre-revenue.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in successful fundraising rounds and advancement of pipeline programs.
Future Projections: Future growth is contingent on successful clinical trials, regulatory approvals, and commercialization of its peptide therapeutics.
Recent Initiatives: Recent initiatives include advancing MBX-2146 into later-stage clinical trials and expanding research efforts in other endocrine disorders.
Summary
MBX Biosciences is an early-stage biopharmaceutical company focused on developing peptide therapeutics for endocrine disorders. Their PET platform offers a promising approach to targeting these diseases. While they face typical biotech risks, their focus on rare conditions and strong IP position provide some insulation. Further funding and successful clinical trials are essential for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Clinical trial databases
- Press releases
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is limited or unavailable as MBX Biosciences is a private company and its products are in early-stage development. Financial data may not be fully available.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MBX Biosciences, Inc. Common Stock
Exchange NASDAQ | Headquaters Carmel, IN, United States | ||
IPO Launch date 2024-09-13 | CEO, President & Director Mr. Peter Kent Hawryluk MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 43 | Website https://mbxbio.com |
Full time employees 43 | Website https://mbxbio.com | ||
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.